Funding for this research was provided by:
National Cancer Institute (CA 123223, CA 123223)
Ministry of National Defense Medical Affair Bureau, Taiwan (MAB-108-079)
Chi Mei Medical Center (CMNDMC10705, CMNDMC10813)
Article History
Received: 31 March 2020
Accepted: 8 April 2020
First Online: 18 April 2020
Compliance with ethical standards
:
: CYL is an inventor on US patents #6,077,938 (Title: Monoclonal antibody to an 80-kDa protease) and #6,677,377 (Title: Structure based discovery of inhibitors of matriptase for the cancer diagnosis and therapy by detection and inhibition of matriptase activity) and MDJ and CYL are inventors on US patent #7,355,015 (Title: Matriptase, a serine protease and its applications). This does not alter our adherence to the journal policies on sharing data and materials and official views of the National Cancer Institute or the National Institutes of Health.